An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
DOI10.1111/BIOM.13116zbMATH Open1451.62129OpenAlexW2955527447WikidataQ91625934 ScholiaQ91625934MaRDI QIDQ5128802FDOQ5128802
Authors: Ruitao Lin, Peter F. Thall, Ying Yuan 
Publication date: 26 October 2020
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/biom.13116
Recommendations
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
missing dataadaptive randomizationoptimal treatment regimeBayesian designphase I-II clinical trialordered subgroups
Applications of statistics to biology and medical sciences; meta analysis (62P10) Missing data (62D10) Response surface designs (62K20)
Cited In (6)
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
- A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
- Change-point joint model for identification of plateau of activity in early phase trials
- Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
This page was built for publication: An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5128802)
